179 related articles for article (PubMed ID: 15102956)
1. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
[TBL] [Abstract][Full Text] [Related]
2. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
Yu L; Waxman DJ
Drug Metab Dispos; 1996 Nov; 24(11):1254-62. PubMed ID: 8937861
[TBL] [Abstract][Full Text] [Related]
3. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
Chen L; Waxman DJ; Chen D; Kufe DW
Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
[TBL] [Abstract][Full Text] [Related]
4. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
Huang Z; Roy P; Waxman DJ
Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
[TBL] [Abstract][Full Text] [Related]
5. 2,2',3,3',6,6'-hexachlorobiphenyl hydroxylation by active site mutants of cytochrome P450 2B1 and 2B11.
Waller SC; He YA; Harlow GR; He YQ; Mash EA; Halpert JR
Chem Res Toxicol; 1999 Aug; 12(8):690-9. PubMed ID: 10458702
[TBL] [Abstract][Full Text] [Related]
6. Escherichia coli expression and characterization of cytochromes P450 2B11, 2B1, and 2B5.
John GH; Hasler JA; He YA; Halpert JR
Arch Biochem Biophys; 1994 Nov; 314(2):367-75. PubMed ID: 7979377
[TBL] [Abstract][Full Text] [Related]
7. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene.
Chen L; Yu LJ; Waxman DJ
Cancer Res; 1997 Nov; 57(21):4830-7. PubMed ID: 9354446
[TBL] [Abstract][Full Text] [Related]
9. Role of residue 480 in substrate specificity of cytochrome P450 2B5 and 2B11.
Liu J; He YA; Halpert JR
Arch Biochem Biophys; 1996 Mar; 327(1):167-73. PubMed ID: 8615687
[TBL] [Abstract][Full Text] [Related]
10. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
11. Structural determinants of progesterone hydroxylation by cytochrome P450 2B5: the role of nonsubstrate recognition site residues.
He YQ; Harlow GR; Szklarz GD; Halpert JR
Arch Biochem Biophys; 1998 Feb; 350(2):333-9. PubMed ID: 9473309
[TBL] [Abstract][Full Text] [Related]
12. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm.
Wei MX; Tamiya T; Rhee RJ; Breakefield XO; Chiocca EA
Clin Cancer Res; 1995 Oct; 1(10):1171-7. PubMed ID: 9815909
[TBL] [Abstract][Full Text] [Related]
13. Interconversion of the androstenedione hydroxylase specificities of cytochromes P450 2B4 and 2B5 upon simultaneous site-directed mutagenesis of four key substrate recognition residues.
He YQ; Szklarz GD; Halpert JR
Arch Biochem Biophys; 1996 Nov; 335(1):152-60. PubMed ID: 8914846
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for the differences in lidocaine binding and regioselectivity of oxidation by cytochromes P450 2B1 and 2B2.
Hanna IH; Roberts ES; Hollenberg PF
Biochemistry; 1998 Jan; 37(1):311-8. PubMed ID: 9425052
[TBL] [Abstract][Full Text] [Related]
15. Role of residues 363 and 206 in conversion of cytochrome P450 2B1 from a steroid 16-hydroxylase to a 15 alpha-hydroxylase.
Luo Z; He YA; Halpert JR
Arch Biochem Biophys; 1994 Feb; 309(1):52-7. PubMed ID: 8117113
[TBL] [Abstract][Full Text] [Related]
16. Site-directed mutagenesis of putative substrate recognition sites in cytochrome P450 2B11: importance of amino acid residues 114, 290, and 363 for substrate specificity.
Hasler JA; Harlow GR; Szklarz GD; John GH; Kedzie KM; Burnett VL; He YA; Kaminsky LS; Halpert JR
Mol Pharmacol; 1994 Aug; 46(2):338-45. PubMed ID: 8078495
[TBL] [Abstract][Full Text] [Related]
17. Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities.
Hanna IH; Teiber JF; Kokones KL; Hollenberg PF
Arch Biochem Biophys; 1998 Feb; 350(2):324-32. PubMed ID: 9473308
[TBL] [Abstract][Full Text] [Related]
18. 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels.
Chang TK; Chen H; Waxman DJ
Drug Metab Dispos; 1994; 22(5):673-9. PubMed ID: 7835216
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of amino acid residues critical for unique activities of rabbit cytochrome P450 2B5 using hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome P450 2B4.
Szklarz GD; He YQ; Kedzie KM; Halpert JR; Burnett VL
Arch Biochem Biophys; 1996 Mar; 327(2):308-18. PubMed ID: 8619620
[TBL] [Abstract][Full Text] [Related]
20. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
